﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Medical Journal of Tabriz University of Medical Sciences</JournalTitle>
      <Issn>2783-2031</Issn>
      <Volume>27</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2006</Year>
        <Month>01</Month>
        <DAY>21</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Effect of Interferon Beta - 1- a on Brain Lesions in MRI Images in Multiple Sclerosis</ArticleTitle>
    <FirstPage>17</FirstPage>
    <LastPage>21</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>A</FirstName>
        <LastName>PASHAPOUR</LastName>
      </Author>
      <Author>
        <FirstName>R</FirstName>
        <LastName>MANSORIZADEH</LastName>
      </Author>
      <Author>
        <FirstName>M</FirstName>
        <LastName>DAGHIGHI</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">
      </ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2011</Year>
        <Month>01</Month>
        <Day>10</Day>
      </PubDate>
    </History>
    <Abstract>Background and Objective: Multiple sclerosis (MS) is a T cell- mediated autoimmune disease with central nervous system lesions which characterized by mononuclear cellular infiltrate, edema, demyelination, and occasionally axonal loss. MS is a chronic disease requiring long-term monitoring of treatment. This study performed to evaluate the effects of interferone beta – 1a on brain lesions of MS patients by then MRI images. Materials and Methods: In this study, 30 patients who had MS criteria were selected. Neurologic examinations were done on them and primary MRI was preformed. Then they were treated with interferon beta-1a for six months. After then, another MRI was preformed and neurologic reexamination done again. We compared results of first and second MRIs and examinations results were analyzed with SPSS, ‍‍Paired T-test &amp; Chi-square. Results were reported in percents and means. The level of meaningfulness was considered as P&lt;0.05. Results: Out of 30 patients, 22 of them were female and 8 of them were males. Mean age at the time of study was 31.2 (SD=5/68) years. There were, decrease of motor signs in 13 cases, decrease of sensory signs in 5 cases, decrease of cerebellar &amp; brain stem signs in 5 cases and decrease of spinal signs in 7 cases. There was decrease in the size of MRI plaques in supratentorium in 17 cases, in cerebellum and brain stem in 14 cases, and in cervical cord in 4 cases. There was decreased number of MRI plaques in supratentorium in 4 cases, cerebellum and brain stem in 10 cases and in spine in 2 cases. In first MRI number of lesions were in 30 cases in supratentorium, 13 cases in infratentorium and 13 cases in spine. Conclusions: Interferon beta-1a is effective in decreasing the size of MRI plaques in MS patients. Also it is useful in decreasing clinical signs.</Abstract>
  </Article>
</ArticleSet>